Wednesday Aug 13
Thiazolidinedione therapy versus lifestyle recommendation in the...
Background Few studies have investigated intervention therapy to reduce steatosis in the liver allograft post-transplantation.
Targeting renal glucose reabsorption for the treatment of type 2...
Sodium-glucose co-transporter 2 plays a key role in glucose homeostasis as the key transporter responsible for most renal glucose reabsorption in the proximal tubules of the kidney.
Ema CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync
Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics for VipidiaTM and the fixed-dose combination therapies VipdometTM and IncresyncTM .
The Ghosts of Litigation Holds Past
Earlier this year, in the widely followed In re: Actos Products Liability Litigation matter, a Louisiana federal jury ordered a drug manufacturer to pay $6 billion in punitive damages and $1.5 million in actual damages.
Diabetes Drug Pioglitazone May Lower Risk of Alzheimer's Disease
According to a report from Reuters, a new German study has suggested that treatment with the diabetes drug pioglitazone may reduce the risk of developing Alzheimer's disease , although conclusive proof could be years away.